Omega 3 vs omega 6 as a complementary treatment for cancer-related fatigue
Dr. Luke Peppone of University of Rochester Medical Center, Rochester, NY discusses results from a preliminary study measuring omega 3 versus omega 6 supplementation for fatigue among breast cancer survivors. Patients were either given a high dose of omega 3 supplements (sourced from fish oil), a high dose of omega 6 supplements (sourced from soybean oil), or a combination of a low dose of both omega 3 and 6. Results show that those with a high dose of omega 6, had a significant reduction in cancer-related fatigue, compared to those in the omega 3 group. This study showed omega 3 and 6 to be relatively safe and although they can’t yet be recommended for fatigue, they are also found to be beneficial in improving sleep and easing the pain. In this video, Dr. Peppone mentions the plans of a larger study around the use of soybean oil to treat cancer-related fatigue and other symptoms. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Ocular Oncology (ISOO) 2016 Annual Meeting on Supportive Care in Cancer held in Adelaide, Australia.
This programme has been supported by Helsinn, through an unrestricted educational grant to the Patient Empowerment Foundation.
Visit our website | http://www.patientpower.eu/
Follow on Twitter | https://twitter.com/patientpowereu
Like on Facebook | https://www.fb.com/patientpower.europe
Видео Omega 3 vs omega 6 as a complementary treatment for cancer-related fatigue канала Patient Power Europe
This programme has been supported by Helsinn, through an unrestricted educational grant to the Patient Empowerment Foundation.
Visit our website | http://www.patientpower.eu/
Follow on Twitter | https://twitter.com/patientpowereu
Like on Facebook | https://www.fb.com/patientpower.europe
Видео Omega 3 vs omega 6 as a complementary treatment for cancer-related fatigue канала Patient Power Europe
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Which patients can most benefit from stem cell transplantation?](https://i.ytimg.com/vi/OGrxlZcY8CM/default.jpg)
![¿Cómo puede saber el paciente cuál es su mejor opción de tratamiento?](https://i.ytimg.com/vi/LFHqDWlb8vI/default.jpg)
![L’accès à l’information médicale de qualité](https://i.ytimg.com/vi/RKQVm-jsa-M/default.jpg)
![Mensaje para los argentinos afectados por cánceres hematológicos](https://i.ytimg.com/vi/zQ6Mc5FmEeI/default.jpg)
![Prof Michele Cavo’s take-home message for patients from the Myeloma 2015 meeting](https://i.ytimg.com/vi/ffohCqJJ8Fo/default.jpg)
![Wie wird eine CLL diagnostiziert und welche Rolle spielen Mutationen bei der Therapiewahl?](https://i.ytimg.com/vi/36xLw4H-Zyw/default.jpg)
![Prof. Dr. Stephan Stilgenbauer über neue Behandlungsmöglichkeiten bei CLL](https://i.ytimg.com/vi/P0qDV8ad_is/default.jpg)
![Empfehlungen für Patienten mit AML](https://i.ytimg.com/vi/xTLtLZzkBHA/default.jpg)
![Dr. Andreas Mumm über die Rehabilitation beim Multiplem Myelom](https://i.ytimg.com/vi/wjzRnrlF2z0/default.jpg)
![Changing your lifestyle following treatment of acute myeloid leukaemia (AML)](https://i.ytimg.com/vi/noZep0nkkHw/default.jpg)
![Le associazioni dei pazienti affetti da neoplasia](https://i.ytimg.com/vi/jlpilHJNQn4/default.jpg)
![New breast cancer data from EBCC9: what does this mean for the patient?](https://i.ytimg.com/vi/H0dE5Tf6xTg/default.jpg)
![Cómo se diagnostica la leucemia linfática crónica](https://i.ytimg.com/vi/vysFhUbXRos/default.jpg)
![Prof. Dr. Stephan Stilgenbauer über die „Watch-and-wait“-Strategie bei asymptomatischer CLL](https://i.ytimg.com/vi/mQrLaB_4Yw8/default.jpg)
![Prof. Dr. Stilgenbauer über Durchbrüche in der Therapie der chronischen lymphatischen Leukämie](https://i.ytimg.com/vi/7tKVF--3IDg/default.jpg)
![Pregnancy in patients with myeloproliferative neoplasms](https://i.ytimg.com/vi/LOtlbj6oXaE/default.jpg)
![How to deal with the emotional stress following an acute leukaemia diagnosis](https://i.ytimg.com/vi/PbMoM8cD5Eo/default.jpg)
![Reduce your fatigue levels with physical activity](https://i.ytimg.com/vi/OIl2MgPyjQU/default.jpg)
![Venetoclax dose-escalation and obinutuzumab treatment schedule in a clinical trial](https://i.ytimg.com/vi/tmUf8muZUYY/default.jpg)
![Chronische lymphatische Leukämie Highlights von ASH 2016](https://i.ytimg.com/vi/P0Tt96-Q6zY/default.jpg)
![Leukämie in Kindern - Unterstützung für die ganze Familie und Normalität](https://i.ytimg.com/vi/ArJ2o5Xz-Lk/default.jpg)